Tacrolimus in rheumatoid arthritis
- 22 December 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 7 (1) , 91-98
- https://doi.org/10.1517/14656566.7.1.91
Abstract
Tacrolimus is an immunosuppressive drug that has been used widely in organ transplantation and topically for atopic dermatitis. Tacrolimus exerts its immunosuppressive effects by the inhibition of calcineurin, leading to interference with T-cell activation. As T-cell activation plays a major role in the pathogenesis of rheumatoid arthritis, there has been an interest in the use of tacrolimus for the treatment of rheumatoid arthritis. The pharmacological properties of tacrolimus have the potential of suppressing the production of inflammatory cytokines, improvement of joint inflammation, improvement of bone and cartilage destruction, improvement of functional status and relief from arthritic pain. This article reviews the pharmacodynamics, pharmacokinetics, clinical efficacy, safety and role of tacrolimus in the treatment of rheumatoid arthritis.Keywords
This publication has 28 references indexed in Scilit:
- Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: Comment on the article by Yocum et alArthritis & Rheumatism, 2004
- Considerations with the use of biological therapy in the treatment of rheumatoid arthritisExpert Opinion on Drug Safety, 2004
- Safety of tacrolimus in patients with rheumatoid arthritis: long-term experienceRheumatology, 2004
- Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double‐blind trialArthritis & Rheumatism, 2003
- Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexateArthritis & Rheumatism, 2003
- Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant‐induced arthritisBritish Journal of Pharmacology, 2003
- Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult PatientsClinical Pharmacokinetics, 2001
- FK506 potently inhibits T cell activation induced TNF‐α and IL‐1β production in vitro by human peripheral blood mononuclear cellsBritish Journal of Pharmacology, 2000
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993